Second, a Phase III trial in metastatic melanoma that tested the peptide vaccine in combination with high-dose IL-2 versus IL-2 alone, showed significant improvement in overall response rates and progression-free survival in patients who received the vaccine [49]. The gene discussed is IL2; the disease is metastatic melanoma.